Skin Biopsy and IENFD

Skin biopsy with intraepidermal nerve fiber density (IENFD) quantification has become the diagnostic standard for small fiber neuropathy (SFN), a condition that is invisible on standard nerve conduction studies and EMG (which test large myelinated fibers). The small unmyelinated C-fibers and thinly myelinated A-delta fibers carry pain, temperature, and autonomic information; their loss produces a distinctive clinical syndrome of burning pain, autonomic dysfunction, and sometimes profound disability — all with normal “standard” electrodiagnostic testing. Recognition of small fiber neuropathy as a distinct, common, and often treatable condition has transformed the workup of patients with painful neuropathy, autonomic symptoms, fibromyalgia-like presentations, and “neuropathy with normal EMG.” This page covers skin biopsy IENFD methodology, the spectrum of small fiber neuropathy, etiologies, and the complementary role of autonomic function testing.

🔹 Bottom Line: Skin Biopsy IENFD & Small Fiber Neuropathy

  • Skin biopsy IENFD is the diagnostic standard for SFN: 3 mm punch at distal leg (10 cm above lateral malleolus), PGP 9.5 staining. Reduced IENFD is defined against age-, sex-, site-, and laboratory-specific normative reference values (typically the lower 5th percentile) — there is no single portable cutoff.
  • Length-dependent SFN: reduced at distal leg, normal at thigh. Non-length-dependent (reduced at thigh / forearm): think immune-mediated — Sjögren ganglionopathy, sarcoidosis, post-viral.
  • Normal EMG does NOT exclude SFN — standard NCS only tests large fibers.
  • Most common etiologies: diabetes, pre-diabetes (HbA1c 5.7–6.4% can cause SFN — easy to miss), idiopathic.
  • Treatment is primarily treatment of the cause + symptom control. Identify and treat the underlying etiology; manage neuropathic pain (gabapentin/pregabalin, duloxetine, topical lidocaine).
  • Immunotherapy is NOT routine for idiopathic SFN — a randomized placebo-controlled IVIG trial in idiopathic painful SFN was negative, and recent neuromuscular guidance advises against routine IVIG use in this group. Reserve immunotherapy for carefully selected immune-mediated cases (e.g., Sjögren-related SFN where the underlying disease is itself an immunotherapy indication).
  • Treatable genetic SFN: Fabry disease (enzyme replacement / chaperone therapy), hereditary TTR amyloidosis (patisiran, inotersen, tafamidis). Test in young patients with painful SFN of unknown cause, especially with renal disease, cardiomyopathy, or young stroke.
  • ~40–50% of patients diagnosed with “fibromyalgia” have demonstrable SFN on skin biopsy — don’t dismiss painful neuropathy with normal EMG as functional.

The Small Fiber System

Fiber Types and Function

  • Unmyelinated C-fibers: slow conduction; carry burning pain, warmth, autonomic (sympathetic).
  • Thinly myelinated A-delta fibers: faster than C; sharp pain, cold sensation.
  • Heavily myelinated A-beta fibers: vibration, proprioception, light touch (NOT tested by skin biopsy or autonomic studies; tested by standard NCS/EMG).

Why Standard EMG Misses Small Fiber Neuropathy

  • NCS measures conduction in large myelinated fibers only.
  • Small fibers are too thin / slow to be reliably measured by surface NCS.
  • Patients with isolated SFN have completely normal NCS/EMG.
  • Skin biopsy IENFD or autonomic testing is required for diagnosis.

Skin Biopsy IENFD Methodology

Technique

  • 3 mm punch biopsy, typically from distal leg (10 cm above lateral malleolus) — standardized site.
  • Local anesthesia.
  • Tissue fixed (Zamboni fixative) and sectioned.
  • Immunostaining for PGP 9.5 (protein gene product 9.5) — pan-axonal marker.
  • Microscopic count of fibers crossing the dermoepidermal junction (DEJ).
  • Result expressed as fibers per mm of epidermis.

Reference Values

  • Age- and sex-normalized normative values published.
  • Lower 5th percentile defines reduced IENFD.
  • Reduced IENFD is defined against age-, sex-, site-, and laboratory-specific normative reference values, usually using the lower 5th percentile cutoff. There is no single universal “fibers/mm” number that applies across all labs and ages — always interpret against the reference normative dataset used by the specific lab.

Pattern Interpretation

  • Length-dependent SFN: reduced IENFD at distal leg, often normal at thigh.
  • Non-length-dependent SFN: reduced at proximal sites (thigh) and distal — suggests immune-mediated or ganglionopathy etiology (e.g., Sjögren).
  • Patchy or asymmetric loss: also suggests immune-mediated.

Biopsy Sites for Pattern Determination

  • Distal leg (always).
  • Thigh (to determine length-dependent vs non-length-dependent).
  • Forearm or proximal arm (for non-length-dependent confirmation).

🔹 Clinical Relevance: SFN Is Real, Treatable, and Often Missed

Studies have suggested that ~40–50% of patients diagnosed with “fibromyalgia” have demonstrable small fiber neuropathy on skin biopsy — meaning some of what is treated as a functional pain syndrome is actually underlying SFN. A normal EMG only rules out large-fiber neuropathy; the small fiber system needs its own evaluation.

  • Burning pain + autonomic features + normal large-fiber exam and normal EMG → consider IENFD before labeling as functional.
  • A positive skin biopsy directs workup, not treatment alone: search for diabetes/pre-diabetes (HbA1c 5.7–6.4% counts), Sjögren, sarcoidosis, B12, B6 toxicity, celiac, HCV/HIV, monoclonal gammopathy.
  • Treatable genetic causes worth not missing: Fabry disease (painful SFN in a young patient, sometimes with renal disease, cardiomyopathy, or young stroke; enzyme replacement available) and hereditary TTR amyloidosis (patisiran, inotersen, tafamidis).
  • Symptomatic management: gabapentin/pregabalin, duloxetine, topical lidocaine; capsaicin patches.
  • Don’t reach for IVIG in idiopathic SFN — the RCT was negative.

Clinical Syndrome of Small Fiber Neuropathy

Sensory Symptoms

  • Burning pain: distal feet and hands; often worse at night.
  • Tingling, pins-and-needles, electric shock-like sensations.
  • Allodynia (touch becomes painful).
  • Hyperalgesia (heightened pain to noxious stimuli).
  • Loss of pain and temperature sensation.
  • Numbness (later, as more severe).

Autonomic Symptoms

  • Orthostatic intolerance (lightheadedness on standing, palpitations).
  • Gastrointestinal dysmotility (early satiety, constipation).
  • Bladder dysfunction.
  • Sexual dysfunction.
  • Sudomotor abnormalities (dry skin distally; impaired sweating; can produce paradoxical heat intolerance).
  • Vasomotor changes (skin color changes, mottling).

Examination Findings (Often Normal!)

  • Standard reflexes preserved.
  • Standard sensory examination often normal (vibration, proprioception intact — these are large-fiber).
  • Pinprick and temperature sensation distal: may be reduced.
  • Skin appearance: dry, atrophic distally in chronic disease.
  • Standard motor strength preserved (small-fiber neuropathy is non-motor).

Common Etiologies of Small Fiber Neuropathy

Metabolic

  • Diabetes mellitus (most common cause overall).
  • Impaired glucose tolerance / pre-diabetes: HbA1c 5.7-6.4% can cause SFN.
  • Metabolic syndrome.
  • Hypothyroidism.

Toxic / Nutritional

  • Alcohol.
  • Chemotherapy (oxaliplatin, taxanes, vincristine, bortezomib, thalidomide).
  • Statins (rare).
  • Vitamin B12 deficiency (small + large fiber).
  • Vitamin B6 toxicity.

Immune-Mediated

  • Sjögren syndrome (often non-length-dependent ganglionopathy pattern).
  • SLE.
  • Sarcoidosis.
  • Celiac disease.
  • Inflammatory bowel disease.
  • Post-viral / post-COVID.
  • Suspected immune-mediated SFN of unclear cause — immunotherapy benefit is not established in randomized data for idiopathic SFN; reserve for carefully selected cases.

Infectious

  • HIV.
  • Hepatitis C.
  • Lyme disease.

Genetic

  • SCN9A, SCN10A, SCN11A mutations (sodium channelopathies).
  • Fabry disease: X-linked α-galactosidase deficiency; SFN often the first manifestation; treatable with enzyme replacement.
  • Familial amyloidosis (TTR, AL).
  • Hereditary sensory and autonomic neuropathies (HSAN).

Amyloidosis

  • Hereditary ATTR amyloidosis (variant TTR): now treatable with patisiran, inotersen, tafamidis.
  • Wild-type ATTR (cardiac predominant; SFN less common).
  • AL amyloidosis (plasma cell dyscrasia).
  • SFN often early manifestation of amyloidosis.
  • Important to recognize because of effective treatments.

Idiopathic SFN

  • ~25-40% of SFN remains idiopathic after workup.
  • Possible undetected immune mechanism.
  • Patients may benefit from symptomatic treatment.

Workup of Suspected Small Fiber Neuropathy

Initial

  • Glucose, HbA1c — diabetes / pre-diabetes screen.
  • TSH.
  • Vitamin B12, B6 (rule out toxicity), folate.
  • Liver function, BUN/creatinine.
  • HIV.
  • Hepatitis C.
  • ANA, anti-SSA/SSB (Sjögren — common cause).
  • ACE (sarcoidosis).
  • SPEP, immunofixation (amyloidosis screen).
  • Celiac panel.

Specialized

  • Skin biopsy with IENFD: distal leg + thigh (for length-dependent vs non-length-dependent pattern).
  • Quantitative sudomotor axon reflex test (QSART): sweat function; complementary to IENFD.
  • Tilt-table test, autonomic function testing (heart rate variability, Valsalva ratio).
  • Genetic testing for hereditary SFN if family history, atypical age, atypical features.
  • Salivary gland biopsy if Sjögren clinically suspected (see Tissue Biopsy page).
  • TTR gene sequencing if amyloidosis suspected (cardiac symptoms, family history, “neuropathy + cardiomyopathy” syndrome).

Autonomic Function Testing (Complementary to IENFD)

QSART (Quantitative Sudomotor Axon Reflex Test)

  • Measures local sweat response to acetylcholine iontophoresis at multiple sites (foot, leg, thigh, arm).
  • Reduced or absent sweat response = sympathetic small-fiber dysfunction.
  • Distal-predominant reduction = length-dependent SFN.
  • Proximal involvement (thigh, arm) = non-length-dependent or ganglionopathy.

Thermoregulatory Sweat Test (TST)

  • Indophenol-based sweat assessment in heated environment.
  • Visualizes anhidrosis pattern across body — distinguishes pre-ganglionic vs post-ganglionic.

Heart Rate Variability / Valsalva Ratio

  • Assesses parasympathetic and sympathetic cardiovascular reflexes.
  • Useful for autonomic neuropathy of any cause.

Tilt Table Test

  • Identifies orthostatic hypotension, neurogenic vs neurally-mediated syncope, POTS.
  • Useful in patients with orthostatic symptoms.

Treatment

A positive skin biopsy should prompt a focused search for an underlying cause; treatment is primarily treatment of the cause plus symptom control. Immunotherapy is not a routine treatment for idiopathic SFN and should be reserved for carefully selected immune-mediated cases. A randomized placebo-controlled IVIG trial in painful idiopathic SFN was negative (Geerts 2021), and recent neuromuscular guidance advises against routine IVIG use for idiopathic SFN.

Etiology-Specific

  • Diabetes / pre-diabetes: glycemic control may improve or stabilize SFN.
  • Sjögren-related SFN: treat the underlying disease (hydroxychloroquine, immunosuppression; IVIG in selected refractory cases) — driven by the systemic indication, not by SFN alone.
  • Sarcoidosis: steroids.
  • Amyloidosis: TTR-modifying therapy (patisiran, inotersen, tafamidis) for hereditary amyloidosis; chemotherapy for AL.
  • Fabry: enzyme replacement therapy.
  • Toxic exposure: removal.
  • B12 deficiency: replacement.

Symptomatic — Neuropathic Pain

  • Gabapentin or pregabalin (first-line).
  • Duloxetine or amitriptyline.
  • Topical lidocaine.
  • Capsaicin patches.
  • Tramadol or low-dose opioids (selective).

Autonomic Symptoms

  • Orthostatic hypotension: midodrine, droxidopa, fludrocortisone; non-pharmacologic measures (compression, increased salt/fluid).
  • Gastroparesis: dietary modification; metoclopramide (with caution for tardive dyskinesia).
  • Bladder symptoms: appropriate urology referral.

Fabry Disease — Treatable Genetic SFN

Why Critical to Identify

  • X-linked α-galactosidase A deficiency.
  • Multisystemic: renal failure, cardiomyopathy, stroke (especially young), painful neuropathy, sweating abnormalities, angiokeratomas.
  • Enzyme replacement therapy (agalsidase α/β) and chaperone therapy (migalastat) available.
  • Family screening important (X-linked inheritance).

When to Test

  • Young patients with painful SFN of unknown etiology.
  • SFN + renal disease, cardiomyopathy, or young stroke.
  • Family history of unexplained pain, renal failure, or sudden cardiac death.
  • Angiokeratomas (red-purple skin lesions in bathing-trunk distribution).

Testing

  • Plasma α-galactosidase A activity (low in males; can be normal in heterozygous females).
  • GLA gene sequencing.

Pitfalls and Pearls

  • Skin biopsy IENFD: diagnostic standard for SFN.
  • 3 mm punch biopsy distal leg: standardized site; PGP 9.5 staining.
  • Length-dependent vs non-length-dependent: non-length-dependent suggests immune (Sjögren, sarcoidosis).
  • Normal EMG does NOT exclude SFN: standard NCS only tests large fibers.
  • SFN symptoms: burning pain + autonomic features + normal large-fiber examination.
  • Most common SFN etiologies: diabetes, pre-diabetes, idiopathic.
  • Immune SFN: Sjögren, sarcoidosis, SLE, celiac, post-COVID.
  • Treatable genetic SFN: Fabry disease, hereditary TTR amyloidosis.
  • QSART: complementary to IENFD; sympathetic axon reflex sweat response.
  • Pre-diabetes (HbA1c 5.7-6.4%): can cause SFN — don’t miss this.
  • Vitamin B6 toxicity: high-dose supplementation can cause SFN-like sensory neuropathy.
  • Fibromyalgia + SFN: ~40-50% of “fibromyalgia” has demonstrable SFN.
  • SFN + renal disease + cardiomyopathy: think Fabry or amyloidosis.
  • Symptomatic treatment: gabapentin/pregabalin, duloxetine, topical lidocaine.
  • Autonomic dysfunction management: midodrine, fludrocortisone, non-pharmacologic measures.
  • Workup labs: HbA1c, B12, ANA, anti-SSA/SSB, ACE, SPEP/IFE, celiac, HCV, HIV.
  • Don’t dismiss “normal EMG” patient with painful neuropathy: skin biopsy IENFD is the test.

References

  1. Lauria G, Cornblath DR, Johansson O, et al. EFNS guidelines on the use of skin biopsy in the diagnosis of peripheral neuropathy. Eur J Neurol. 2005;12(10):747-758.
  2. Lauria G, Hsieh ST, Johansson O, et al. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on the use of skin biopsy in the diagnosis of small fiber neuropathy. J Peripher Nerv Syst. 2010;15(2):79-92.
  3. Themistocleous AC, Ramirez JD, Serra J, Bennett DLH. The clinical approach to small fibre neuropathy and painful channelopathy. Pract Neurol. 2014;14(6):368-379.
  4. Oaklander AL, Herzog ZD, Downs HM, Klein MM. Objective evidence that small-fiber polyneuropathy underlies some illnesses currently labeled as fibromyalgia. Pain. 2013;154(11):2310-2316.
  5. Tavee J, Zhou L. Small fiber neuropathy: A burning problem. Cleve Clin J Med. 2009;76(5):297-305.
  6. Coelho T, Maia LF, Martins da Silva A, et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology. 2012;79(8):785-792.
  7. Geerts M, et al. IVIG in painful idiopathic small fiber neuropathy: a randomized placebo-controlled trial. Neurology. 2021 (negative trial).